

Johan W Mouton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/830952/publications.pdf>

Version: 2024-02-01

275
papers

16,774
citations

15504

65
h-index

19749

117
g-index

280
all docs

280
docs citations

280
times ranked

14247
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 934-943.	3.0	5
2	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) <i>TJ ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>		
3	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on <i>Mycobacterium tuberculosis</i> . <i>Clinical Microbiology and Infection</i> , 2021, 27, 288.e1-288.e4.	6.0	9
4	The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab070.	0.9	16
5	In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against <i>Candida krusei</i> but not <i>Candida glabrata</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106291.	2.5	6
6	Evaluation of the post-antibiotic effect in vivo for the combination of a β -lactam antibiotic and a β -lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections. <i>Journal of Chemotherapy</i> , 2021, 33, 400-408.	1.5	1
7	Activity of Cefepime in Combination with the Novel β -Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum- β -Lactamase-Producing Isolates in <i>In Vitro</i> Checkerboard Assays. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	15
8	The Role of New Posaconazole Formulations in the Treatment of <i>Candida albicans</i> Infections: Data from an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
9	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. <i>BMC Infectious Diseases</i> , 2021, 21, 309.	2.9	4
10	The synthetic synergistic cinnamon oil CIN-102 is active against <i>Madurella mycetomatis</i> , the most common causative agent of mycetoma. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009488.	3.0	3
11	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against <i>Enterobacterales</i> , <i>Pseudomonas aeruginosa</i> and <i>Enterococcus</i> spp. in an in vitro bladder infection model: impact on clinical breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3201-3211.	3.0	3
12	Zinc-Impregnated Mesh for Abdominal Wall Repair Reduces Infection in a Rat Model of Peritonitis. <i>Journal of Surgical Research</i> , 2020, 246, 560-567.	1.6	3
13	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 303-317.	2.4	37
14	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 988-996.	3.0	13
15	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against <i>Enterobacterales</i> : the Importance of Heteroresistance for Growth Outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
16	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 791-797.	2.9	51
17	Cefpirome Treatment Results in Limited Selection of Stable Derepressed <i>Enterobacter cloacae</i> Mutants in the Intestinal Flora of Rats Treated for an Experimental <i>Klebsiella pneumoniae</i> Pulmonary Infection. <i>Microbial Drug Resistance</i> , 2020, 26, 341-348.	2.0	0
18	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. <i>Clinical Infectious Diseases</i> , 2020, 71, 2599-2607.	5.8	10

#	ARTICLE	IF	CITATIONS
19	Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates – the EUCAST broth microdilution reference method for MIC determination. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1488-1492.	6.0	49
20	Exploring the Interplay of Resistance Nodulation Division Efflux Pumps, <i>Amp^C</i> and <i>Opr^D</i> in Antimicrobial Resistance of <i>Burkholderia cepacia</i> Complex in Clinical Isolates. <i>Microbial Drug Resistance</i> , 2020, 26, 1144-1152.	2.0	6
21	Efficacy of single and multiple oral doses of fosfomycin against <i>Pseudomonas aeruginosa</i> urinary tract infections in a dynamic in vitro bladder infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1879-1888.	3.0	9
22	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <i>Candida albicans</i> Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
23	Trends, seasonality and the association between outpatient antibiotic use and antimicrobial resistance among urinary bacteria in the Netherlands. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2314-2325.	3.0	12
24	Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2650-2656.	3.0	9
25	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	19
26	Guide-free Cas9 from pathogenic <i>Campylobacter jejuni</i> bacteria causes severe damage to DNA. <i>Science Advances</i> , 2020, 6, eaaz4849.	10.3	31
27	Study protocol for an international, multicentre stepped-wedge cluster randomised trial to evaluate the impact of a digital antimicrobial stewardship smartphone application. <i>BMJ Open</i> , 2020, 10, e033640.	1.9	4
28	Methodological features of clinical pharmacokinetic–pharmacodynamic studies of antibacterials and antifungals: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1374-1389.	3.0	19
29	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. <i>Journal of Microbiological Methods</i> , 2020, 171, 105861.	1.6	15
30	Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. <i>Clinical Pharmacokinetics</i> , 2020, 59, 885-898.	3.5	9
31	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: <i>in vitro</i> synergism is not associated with better clinical outcomes. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1185-1191.	6.0	46
32	A multicentre study to optimize echinocandin susceptibility testing of <i>Aspergillus</i> species with the EUCAST methodology and a broth microdilution colorimetric method. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1799-1806.	3.0	10
33	Bacterial quantification in tissue homogenates from <i>in vivo</i> pharmacodynamic studies using growth curves. <i>Journal of Medical Microbiology</i> , 2020, 69, 676-684.	1.8	2
34	Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 435-441.	2.5	9
35	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2247-2254.	3.0	8
36	Polymyxin Susceptibility Testing and Breakpoint Setting. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 117-132.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Invasive Aspergillosis by <i>Aspergillus flavus</i> : Epidemiology, Diagnosis, Antifungal Resistance, and Management. <i>Journal of Fungi</i> (Basel, Switzerland), 2019, 5, 55.	3.5	149
38	Voriconazole efficacy against <i>Candida glabrata</i> and <i>Candida krusei</i> : preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 140-148.	3.0	4
39	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39.	2.6	545
40	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 112.	3.5	13
41	Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 161-167.	2.8	9
42	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1333-1343.	3.5	11
43	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1761-1762.	3.0	7
44	Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?. <i>Drug Resistance Updates</i> , 2019, 43, 1-9.	14.4	17
45	The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1656-1661.	3.0	18
46	In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	7
47	An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 34-39.	2.5	37
48	Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in checkerboard assays against carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 387-394.	3.0	15
49	Treatment Outcomes of Colistin- and Carbapenem-resistant <i>Acinetobacter baumannii</i> Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 769-776.	5.8	83
50	Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
51	A New Marker of Echinocandin Activity in an In Vitro Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of <i>Aspergillus fumigatus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	1
52	Colistin versus colistin plus meropenem for severe infections Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 495-496.	9.1	1
53	Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1781.	7.4	147
54	Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00378.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 391-400.	9.1	400
56	Exploring colistin pharmacodynamics against <i>Klebsiella pneumoniae</i> : a need to revise current susceptibility breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 953-961.	3.0	21
57	MIC-based dose adjustment: facts and fables. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 564-568.	3.0	233
58	Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 469-476.	3.0	15
59	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 709-719.	3.0	30
60	Isavuconazole susceptibility of clinical <i>Aspergillus fumigatus</i> isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 134-142.	3.0	29
61	Soup with or without meatballs: Impact of nutritional factors on the MIC, kill-rates and growth-rates. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 125, 23-27.	4.0	12
62	The stability of antimycobacterial drugs in media used for drug susceptibility testing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 305-308.	1.8	21
63	MIC-based dose adjustment: facts and fables – authors’ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2585-2586.	3.0	10
64	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2374-2379.	3.0	65
65	Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2916-2926.	3.0	88
66	Susceptibility of ESBL <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2380-2387.	3.0	45
67	Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. <i>Pharmacological Research</i> , 2018, 134, 280-288.	7.1	94
68	<i>In Vitro</i> Antifungal Susceptibility Testing of <i>Candida</i> Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	30
69	Shortening the incubation time for antimicrobial susceptibility testing by disk diffusion for Enterobacteriaceae: how short can it be and are the results accurate?. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 631-637.	2.5	27
70	<i>In Vivo</i> Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant <i>Aspergillus fumigatus</i> Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	5
71	Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole. <i>Medical Mycology Case Reports</i> , 2017, 16, 16-19.	1.3	20
72	Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3366-3373.	3.0	18

#	ARTICLE	IF	CITATIONS
73	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3325-3333.	3.0	39
74	Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3374-3381.	3.0	25
75	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	75
76	A fast and sensitive LC-MS/MS method for the quantification of fosfomycin in human urine and plasma using one sample preparation method and HILIC chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 263-269.	2.3	33
77	Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
78	Shortening the incubation time for the combination disk diffusion extended-spectrum β -lactamase (ESBL) confirmation test: how far can we go?. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 473-476.	2.5	0
79	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant <i>Aspergillus flavus</i> Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
80	The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 13-23.	0.7	37
81	Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 172-180.	3.0	6
82	Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3435-3442.	3.0	13
83	Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
84	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. <i>BMJ Open</i> , 2016, 6, e009956.	1.9	41
85	General Concepts of Pharmacodynamics for Anti-infective Agents. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 3-27.	0.2	5
86	Hydrogen cyanide emission in the lung by <i>Staphylococcus aureus</i> . <i>European Respiratory Journal</i> , 2016, 48, 577-579.	6.7	10
87	Tigecycline Is Highly Efficacious against <i>Mycobacterium abscessus</i> Pulmonary Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2895-2900.	3.2	54
88	Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of <i>Mycobacterium abscessus</i> Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3779-3785.	3.2	25
89	Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7272-7279.	3.2	30
90	Dose optimization of voriconazole/anidulafungin combination against <i>Aspergillus fumigatus</i> using an <i>in vitro</i> pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3135-3147.	3.0	18

#	ARTICLE	IF	CITATIONS
91	Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6374-6376.	3.2	41
92	Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2883-2889.	3.0	23
93	Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2909-2917.	3.0	59
94	Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1097-1105.	3.2	85
95	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1013-1021.	3.2	53
96	Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1242-1248.	3.2	41
97	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 368-375.	3.2	87
98	Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 847-856.	9.1	526
99	Bacteroides fragilis in biopsies of patients with major abscesses and diabetic foot infections: direct molecular versus culture-based detection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 263-265.	1.8	3
100	The Strength of Synergistic Interaction between Posaconazole and Caspofungin Depends on the Underlying Azole Resistance Mechanism of Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1738-1744.	3.2	25
101	Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 9-27.	4.4	37
102	Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2299-2304.	3.2	43
103	Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2838-2843.	3.0	21
104	Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2456-2464.	3.0	189
105	Reviving old antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2177-2181.	3.0	79
106	Antimicrobial prescription patterns of veterinarians: introduction of a benchmarking approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2423-2425.	3.0	28
107	Genetic Variation in <i>TLR10</i> , an Inhibitory Toll-Like Receptor, Influences Susceptibility to Complicated Skin and Skin Structure Infections. <i>Journal of Infectious Diseases</i> , 2015, 212, 1491-1499.	4.0	22
108	Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2074-2077.	3.0	47

#	ARTICLE	IF	CITATIONS
109	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 136-153.	2.1	134
110	Pharmacodynamics of Isavuconazole in an <i>Aspergillus fumigatus</i> Mouse Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2855-2866.	3.2	60
111	Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1487-1494.	3.2	22
112	A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in <i>Aspergillus flavus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6615-6619.	3.2	58
113	<i>In Vitro</i> Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum- β -Lactamase-Harboring Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4521-4525.	3.2	19
114	<i>Aspergillus</i> and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. <i>Medical Mycology</i> , 2015, 53, 765-797.	0.7	172
115	<i>In Vitro</i> Activity of Ceftazidime-Avibactam Combination in <i>In Vitro</i> Checkerboard Assays. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1138-1144.	3.2	37
116	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 891-898.	3.0	71
117	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an <i>in vitro</i> pharmacokinetic/pharmacodynamic model—authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 634-635.	3.0	4
118	Pharmacodynamics of Imipenem in Combination with β -Lactamase Inhibitor MK7655 in a Murine Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 790-795.	3.2	37
119	Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 811-817.	3.0	66
120	Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2964-2967.	3.2	13
121	Isolation of ciprofloxacin-resistant <i>Legionella pneumophila</i> in a patient with severe pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2869-2871.	3.0	43
122	Continuous Infusion of Beta-lactam Antibiotics. , 2014, , 223-255.		1
123	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an <i>in vitro</i> pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1611-1619.	3.0	28
124	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 498-509.	9.1	745
125	Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. <i>Clinical Infectious Diseases</i> , 2014, 58, 139-141.	5.8	60
126	Reduced subcutaneous tissue distribution of ceftazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 715-723.	3.0	113

#	ARTICLE	IF	CITATIONS
127	EUCAST Testing of Isavuconazole Susceptibility in Aspergillus: Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6432-6436.	3.2	12
128	Inhaled antibiotics: dry or wet?. <i>European Respiratory Journal</i> , 2014, 44, 1308-1318.	6.7	52
129	Black Yeasts and Their Filamentous Relatives: Principles of Pathogenesis and Host Defense. <i>Clinical Microbiology Reviews</i> , 2014, 27, 527-542.	13.6	94
130	The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. <i>Drug Resistance Updates</i> , 2014, 17, 37-50.	14.4	89
131	Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 117-122.	2.2	5
132	Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening <i>Candida</i> Infections. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1033-1033.	5.6	2
133	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 931-941.	4.4	65
134	A structural comparison of lipopolysaccharide biosynthesis loci of <i>Legionella pneumophila</i> serogroup 1 strains. <i>BMC Microbiology</i> , 2013, 13, 198.	3.3	18
135	Controlling antimicrobial resistance: Interfering in the process of natural selection. <i>Antimicrobial Resistance and Infection Control</i> , 2013, 2, 32.	4.1	2
136	Correlation of MIC value and disk inhibition zone diameters in clinical <i>Legionella pneumophila</i> serogroup 1 isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 339-342.	1.8	17
137	Global survey of polymyxin use: A call for international guidelines. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 131-134.	2.2	42
138	Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 80-82.	2.5	23
139	Inhibitory and Fungicidal Effects of Antifungal Drugs against <i>Aspergillus</i> Species in the Presence of Serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1625-1631.	3.2	21
140	EUCAST expert rules in antimicrobial susceptibility testing. <i>Clinical Microbiology and Infection</i> , 2013, 19, 141-160.	6.0	527
141	Azole-Resistant <i>Aspergillus fumigatus</i> , Iran. <i>Emerging Infectious Diseases</i> , 2013, 19, 832-834.	4.3	58
142	<i>In Vitro</i> Interaction of Voriconazole and Anidulafungin against Triazole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 796-803.	3.2	35
143	Pharmacodynamics and Dose-Response Relationships of Liposomal Amphotericin B against Different Azole-Resistant <i>Aspergillus fumigatus</i> Isolates in a Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1866-1871.	3.2	38
144	Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2047-2053.	3.2	26

#	ARTICLE	IF	CITATIONS
145	Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 900-906.	3.0	105
146	Amphotericin B- and Voriconazole-Echinocandin Combinations against <i>Aspergillus</i> spp.: Effect of Serum on Inhibitory and Fungicidal Interactions. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4656-4663.	3.2	32
147	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 385-393.	3.0	60
148	Combination of Pantothenamides with Vanin Inhibitors as a Novel Antibiotic Strategy against Gram-Positive Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4794-4800.	3.2	32
149	Pharmacodynamics of Anidulafungin against Clinical <i>Aspergillus fumigatus</i> Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 303-308.	3.2	16
150	The Therapeutic Effect of Tigecycline, Unlike That of Ceftazidime, Is Not Influenced by whether the <i>Klebsiella pneumoniae</i> Strain Produces Extended-Spectrum β -Lactamases in Experimental Pneumonia in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 643-646.	3.2	11
151	Composite Survival Index to Compare Virulence Changes in Azole-Resistant <i>Aspergillus fumigatus</i> Clinical Isolates. <i>PLoS ONE</i> , 2013, 8, e72280.	2.5	20
152	Consumption of Antimicrobials in Pigs, Veal Calves, and Broilers in The Netherlands: Quantitative Results of Nationwide Collection of Data in 2011. <i>PLoS ONE</i> , 2013, 8, e77525.	2.5	106
153	Extensive Genetic Diversity within the Dutch Clinical <i>Cryptococcus neoformans</i> Population. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1918-1926.	3.9	53
154	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. <i>Clinical Microbiology and Infection</i> , 2012, 18, E37-E45.	6.0	232
155	Wild-type MIC distribution and epidemiological cut-off values in clinical <i>Legionella pneumophila</i> serogroup 1 isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 103-108.	1.8	47
156	A role for TLR1, TLR2 and NOD2 in cytokine induction by <i>Bacteroides fragilis</i> . <i>Cytokine</i> , 2012, 60, 861-869.	3.2	8
157	Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. <i>Drug Resistance Updates</i> , 2012, 15, 149-161.	14.4	257
158	The Pharmacokinetics and Pharmacodynamics of Pulmonary <i>Mycobacterium avium</i> Complex Disease Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 559-565.	5.6	175
159	Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia. <i>Clinical Infectious Diseases</i> , 2012, 54, 268-274.	5.8	81
160	Resistance of Asian <i>Cryptococcus neoformans</i> Serotype A Is Confined to Few Microsatellite Genotypes. <i>PLoS ONE</i> , 2012, 7, e32868.	2.5	42
161	Protein Binding: Do We Ever Learn?. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3067-3074.	3.2	212
162	Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. <i>Current Opinion in Pharmacology</i> , 2011, 11, 486-493.	3.5	16

#	ARTICLE	IF	CITATIONS
163	Update on antibacterial and antifungal drugs – can we master the resistance crisis?. <i>Current Opinion in Pharmacology</i> , 2011, 11, 429-432.	3.5	16
164	In vitro activity of isavuconazole against 208 <i>Aspergillus flavus</i> isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 370-377.	1.8	42
165	Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. <i>Drug Resistance Updates</i> , 2011, 14, 107-117.	14.4	175
166	In vitro susceptibility of 188 clinical and environmental isolates of <i>Aspergillus flavus</i> for the new triazole isavuconazole and seven other antifungal drugs. <i>Mycoses</i> , 2011, 54, e583-9.	4.0	46
167	Relationship between pharmacodynamic indices and killing patterns in vitro. <i>Future Microbiology</i> , 2011, 6, 613-616.	2.0	4
168	Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to <i>Aspergillus fumigatus</i> with Attenuated Susceptibility to Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3564-3566.	3.2	35
169	Clinical Impact of Preincubation of Blood Cultures at 37°C. <i>Journal of Clinical Microbiology</i> , 2011, 49, 275-280.	3.9	20
170	Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis. <i>Human Reproduction Update</i> , 2011, 17, 301-310.	10.8	35
171	Method for Phenotypic Detection of Extended-Spectrum Beta-Lactamases in <i>Enterobacter</i> Species in the Routine Clinical Setting. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2711-2713.	3.9	12
172	Pharmacokinetics of Clindamycin in Pregnant Women in the Peripartum Period. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2175-2181.	3.2	41
173	Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2141-2148.	3.0	154
174	Evaluation of Etest To Determine Tigecycline MICs for <i>Enterobacter</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2746-2747.	3.2	12
175	Impact of <i>cyp51A</i> Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4758-4764.	3.2	80
176	Efficacy of Posaconazole against Three Clinical <i>Aspergillus fumigatus</i> Isolates with Mutations in the <i>cyp51A</i> Gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 860-865.	3.2	110
177	Pharmacodynamics of anti-infective agents. , 2010, , 49-59.		0
178	Pharmacokinetics of Amoxicillin in Maternal, Umbilical Cord, and Neonatal Sera. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1574-1580.	3.2	18
179	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. <i>Medical Mycology</i> , 2009, 47, 802-807.	0.7	9
180	5-Flucytosine. , 2009, , 307-315.		0

#	ARTICLE	IF	CITATIONS
181	Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 108.e1-108.e6.	1.3	18
182	Concentration-dependency of β -lactam-induced filament formation in Gram-negative bacteria. <i>Clinical Microbiology and Infection</i> , 2008, 14, 344-349.	6.0	51
183	The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 866-874.	2.4	23
184	Rapid and reliable identification of <i>Streptococcus anginosus</i> group isolates to the species level by real-time PCR and melting curve analysis. <i>Journal of Microbiological Methods</i> , 2008, 75, 372-374.	1.6	10
185	Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 382-388.	3.0	78
186	In Vitro Activities at pH 5.0 and pH 7.0 and In Vivo Efficacy of Flucytosine against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4483-4485.	3.2	26
187	Therapeutic Drug Monitoring of Voriconazole. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 403-411.	2.0	116
188	Tissue concentrations: do we ever learn?. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 235-237.	3.0	333
189	Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3049-3055.	3.2	50
190	Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3599-3604.	3.2	119
191	Continuous administration of PBP-2- and PBP-3-specific β -lactams causes higher cytokine responses in murine <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> sepsis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 926-933.	3.0	24
192	Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3720-3725.	3.2	23
193	Effect of Dosing and Dosing Frequency on the Efficacy of Ceftizoxime and the Emergence of Ceftizoxime Resistance during the Early Development of Murine Abscesses Caused by <i>Bacteroides fragilis</i> and <i>Enterobacter cloacae</i> Mixed Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3605-3611.	3.2	27
194	Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3449-3451.	3.2	67
195	Continuous infusion of beta-lactams. <i>Current Opinion in Critical Care</i> , 2007, 13, 598-606.	3.2	92
196	Applying Pharmacodynamics for Susceptibility Breakpoint Selection and Susceptibility Testing. <i>Infectious Disease and Therapy</i> , 2007, , 21-44.	0.0	9
197	The Predictive Value of Laboratory Tests for Efficacy of Antibiotic Combination Therapy. <i>Infectious Disease and Therapy</i> , 2007, , 103-128.	0.0	5
198	Pharmacokinetics and Pharmacodynamics of Azoles. <i>Infectious Disease and Therapy</i> , 2007, , 327-354.	0.0	3

#	ARTICLE	IF	CITATIONS
199	European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. <i>Clinical Microbiology and Infection</i> , 2006, 12, 501-503.	6.0	176
200	Eucast Technical Note on daptomycin. <i>Clinical Microbiology and Infection</i> , 2006, 12, 599-601.	6.0	30
201	Pathophysiology of in-vitro induced filaments, spheroplasts and rod-shaped bacteria in neutropenic mice. <i>Clinical Microbiology and Infection</i> , 2006, 12, 1105-1111.	6.0	8
202	EUCAST Technical Note on linezolid. <i>Clinical Microbiology and Infection</i> , 2006, 12, 1243-1245.	6.0	9
203	EUCAST Technical Note on tigecycline. <i>Clinical Microbiology and Infection</i> , 2006, 12, 1147-1149.	6.0	72
204	Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental <i>Klebsiella pneumoniae</i> Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2919-2925.	3.2	25
205	In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among <i>Streptococcus pneumoniae</i> isolates in The Netherlands: the DUEL 2 study. <i>Clinical Microbiology and Infection</i> , 2005, 11, 312-318.	6.0	7
206	Impact of Pharmacodynamics on Dosing Schedules: Optimizing Efficacy, Reducing Resistance, and Detection of Emergence of Resistance. , 2005, , 387-407.		1
207	Use of a Novel Panel of Nine Short Tandem Repeats for Exact and High-Resolution Fingerprinting of <i>Aspergillus fumigatus</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4112-4120.	3.9	230
208	Duration of antibiotic treatment: are even numbers odd?. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 441-442.	3.0	5
209	Molecular Detection of the Macrolide Efflux Gene: To Discriminate or Not To Discriminate between <i>mef</i> (A) and <i>mef</i> (E). <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1271-1278.	3.2	54
210	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 601-607.	3.0	448
211	Rapid and reliable real-time PCR assay for detection of the macrolide efflux gene and subsequent discrimination between its distinct subclasses <i>mef</i> (A) and <i>mef</i> (E). <i>Journal of Microbiological Methods</i> , 2005, 60, 269-273.	1.6	8
212	A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. <i>Clinical Therapeutics</i> , 2005, 27, 762-772.	2.5	55
213	Pharmacodynamics of tobramycin in patients with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 123-127.	1.8	62
214	Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics. <i>Clinical Pharmacokinetics</i> , 2005, 44, 201-210.	3.5	131
215	Relationship Between Minimum Inhibitory Concentration and Stationary Concentration Revisited. <i>Clinical Pharmacokinetics</i> , 2005, 44, 767-768.	3.5	26
216	New dosing strategies for antibacterial agents in the neonate. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 185-194.	2.3	88

#	ARTICLE	IF	CITATIONS
217	Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. <i>Medical Mycology</i> , 2005, 43, 133-152.	0.7	99
218	Potent Synergistic In Vitro Interaction between Nonantimicrobial Membrane-Active Compounds and Itraconazole against Clinical Isolates of <i>Aspergillus fumigatus</i> Resistant to Itraconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1335-1343.	3.2	55
219	Which cephalosporin for gonorrhoea?. <i>Sexually Transmitted Infections</i> , 2004, 80, 386-388.	1.9	22
220	Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1713-1718.	3.2	73
221	Amplified Fragment Length Polymorphism Fingerprinting Is an Effective Technique To Distinguish <i>Streptococcus pneumoniae</i> from Other Streptococci and an Efficient Alternative to Pulsed-Field Gel Electrophoresis for Molecular Typing of Pneumococci. <i>Journal of Clinical Microbiology</i> , 2004, 42, 369-371.	3.9	10
222	Comparative Study of the Effects of Ceftizoxime, Piperacillin, and Piperacillin-Tazobactam Concentrations on Antibacterial Activity and Selection of Antibiotic-Resistant Mutants of <i>Enterobacter cloacae</i> and <i>Bacteroides fragilis</i> In Vitro and In Vivo in Mixed-Infection Abscesses. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1688-1698.	3.2	22
223	Pneumolysin Is a Key Factor in Misidentification of Macrolide-Resistant <i>Streptococcus pneumoniae</i> and Is a Putative Virulence Factor of <i>S. mitis</i> and Other Streptococci. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4355-4357.	3.9	39
224	Vancomycin. <i>Clinical Pharmacokinetics</i> , 2004, 43, 417-440.	3.5	128
225	Impact of pharmacodynamics on breakpoint selection for susceptibility testing. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 579-598.	5.1	45
226	European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 145-148.	3.0	323
227	In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical <i>Scedosporium prolificans</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 106-117.	3.2	234
228	Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 65-70.	3.0	14
229	Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 541-547.	3.2	51
230	In vitro susceptibilities of zygomycetes to conventional and new antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 45-52.	3.0	299
231	Letters to the Editor. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 256-257.	2.0	4
232	Effect of a Single Percutaneous Abscess Drainage Puncture and Imipenem Therapy, Alone or in Combination, in Treatment of Mixed-Infection Abscesses in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3712-3718.	3.2	15
233	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2876-2885.	3.9	59
234	Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic <i>Pseudomonas aeruginosa</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2575-2581.	3.2	43

#	ARTICLE	IF	CITATIONS
235	In Vitro Activities of New and Conventional Antifungal Agents against Clinical <i>Scedosporium</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 62-68.	3.2	230
236	Why the AUC/MIC Ratio Should Not Be Used to Predict the Effects of β -Lactams. <i>Clinical Infectious Diseases</i> , 2002, 35, 209-210.	5.8	3
237	Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1953-1959.	3.2	50
238	In vitro susceptibilities of Zygomycota to polyenes. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 741-744.	3.0	17
239	Method for Measuring Postantifungal Effect in <i>Aspergillus</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1960-1965.	3.2	24
240	In Vitro Activities of Pentamidine, Pyrimethamine, Trimethoprim, and Sulfonamides against <i>Aspergillus</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2029-2031.	3.2	23
241	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. <i>Reviews in Medical Microbiology</i> , 2002, 13, 101-117.	0.9	13
242	Breakpoints: current practice and future perspectives. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 323-331.	2.5	65
243	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 355-358.	2.5	91
244	The epidemiology of vaginal colonisation with group B streptococci in a sexually transmitted disease clinic. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2002, 105, 177-180.	1.1	24
245	Extended-Interval dosing of tobramycin in neonates: Implications for therapeutic drug monitoring. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 349-358.	4.7	33
246	The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. <i>Clinical Microbiology and Infection</i> , 2001, 7, 486-491.	6.0	17
247	Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfonylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4256-4263.	3.9	71
248	In Vivo Efficacy of Trovafloxacin against <i>Bacteroides fragilis</i> in Mixed Infection with either <i>Escherichia coli</i> or a Vancomycin-Resistant Strain of <i>Enterococcus faecium</i> in an Established-Abscess Murine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1394-1401.	3.2	17
249	Colorimetric Assay for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3402-3408.	3.9	148
250	Improved Efficacy of Ciprofloxacin Administered in Polyethylene Glycol-Coated Liposomes for Treatment of <i>Klebsiella pneumoniae</i> Pneumonia in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1487-1492.	3.2	43
251	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. <i>Aids</i> , 2001, 15, 1067-1068.	2.2	7
252	Combination chemotherapy for the treatment of invasive infections by <i>Scedosporium prolificans</i> . <i>Clinical Microbiology and Infection</i> , 2000, 6, 336-337.	6.0	39

#	ARTICLE	IF	CITATIONS
253	Aerosol therapy in cystic fibrosis: A survey of 54 CF centers. <i>Pediatric Pulmonology</i> , 2000, 30, 368-376.	2.0	26
254	Vancomycin population pharmacokinetics in neonates. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 360-367.	4.7	83
255	In Vitro Interaction of Terbinafine with Itraconazole against Clinical Isolates of <i>Scedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 470-472.	3.2	105
256	Antibiotic treatment in cystic fibrosis. <i>Antimicrobics and Infectious Diseases Newsletter</i> , 2000, 18, 25-29.	0.0	1
257	Antibiotic treatment in cystic fibrosis. <i>Antimicrobics and Infectious Diseases Newsletter</i> , 2000, 18, 33-37.	0.0	0
258	Comparative Pharmacokinetics of the Carbapenems. <i>Clinical Pharmacokinetics</i> , 2000, 39, 185-201.	3.5	175
259	Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2949-2954.	3.9	203
260	Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2473-2478.	3.2	66
261	Lung clearance of intratracheally instilled 99m Tc-tobramycin using pulmonary surfactant as vehicle. <i>British Journal of Pharmacology</i> , 1999, 126, 1091-1096.	5.4	23
262	Pharmacokinetic Optimisation of Antibacterial Treatment in Patients with Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 1998, 35, 437-459.	3.5	60
263	Use of Pharmacodynamic Parameters To Predict Efficacy of Combination Therapy by Using Fractional Inhibitory Concentration Kinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 744-748.	3.2	70
264	Duration and Clinical Relevance of Postantibiotic Effect in Relation to the Dosing Interval. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 749-754.	3.2	34
265	Comparison of Pharmacodynamics of Azithromycin and Erythromycin In Vitro and In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 377-382.	3.2	54
266	Tobramycin population pharmacokinetics in neonates*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 392-399.	4.7	47
267	Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. <i>British Journal of Pharmacology</i> , 1996, 118, 593-598.	5.4	31
268	Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with <i>Klebsiella pneumoniae</i> . <i>British Journal of Pharmacology</i> , 1996, 119, 1145-1148.	5.4	53
269	Typing of <i>Pseudomonas aeruginosa</i> strains from patients with cystic fibrosis: phenotyping versus genotyping. <i>Clinical Microbiology and Infection</i> , 1996, 1, 261-265.	6.0	21
270	Reduction of Surgical-Site Infections in Cardiothoracic Surgery by Elimination of Nasal Carriage of <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 1996, 17, 780-785.	1.8	202

#	ARTICLE	IF	CITATIONS
271	Meropenem Clinical Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1995, 28, 275-286.	3.5	102
272	Emergence of antibiotic resistance amongst <i>Pseudomonas aeruginosa</i> isolates from patients with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 919-926.	3.0	73
273	Oral Immunization with Polyvalent Bacterial Lysate and Infection with <i>Streptococcus pneumoniae</i> : Influence on Interferon-Gamma and PMN Elastase Concentrations in Murine Bronchoalveolar Lavage Fluid. <i>International Archives of Allergy and Immunology</i> , 1992, 97, 173-177.	2.1	9
274	Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 911-918.	3.0	45
275	Antibacterial Therapy in Cystic Fibrosis. <i>Medical Clinics of North America</i> , 1990, 74, 837-850.	2.5	20